SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)

被引：0

作者：

Tedeschi, A. ^{[1
]}

Trotman, J. ^{[2
,3
]}

Zinzani, P. ^{[4
]}

Cavallo, F. ^{[5
]}

Marasca, R. ^{[6
]}

Liberati, A. ^{[7
]}

Linton, K. ^{[8
]}

Mckay, P. ^{[9
]}

Hu, B. ^{[10
]}

Coleman, M. ^{[11
]}

Ardeshna, K. ^{[12
,13
]}

Bijou, F. ^{[14
]}

Marcus, R. ^{[15
]}

Portell, C. ^{[16
]}

Thieblemont, C. ^{[17
]}

Bachy, E. ^{[18
]}

Costello, R. ^{[19
]}

Iyengar, S. ^{[20
]}

Mocikova, H. ^{[21
]}

Co, M. ^{[22
,23
]}

Li, X. ^{[22
,23
]}

Zhou, W. ^{[22
,23
]}

Cappellini, M. ^{[22
,23
]}

Tankersley, C. ^{[22
,23
]}

Huang, J. ^{[22
,23
]}

Opat, S. ^{[24
,25
]}

机构：

[1] ASST Grande Osped Metropolitano Niguarda, Milan, Italy

[2] Concord Repatriat Gen Hosp, Concord, Australia

[3] Univ Sydney, Sydney, NSW, Australia

[4] Univ Bologna, Inst Hematol Serognoli, Bologna, Italy

[5] Azienda Osped Citto Salute & Sci Torino, Turin, Italy

[6] AOU Policlin Modena, Modena, Italy

[7] Azienda Osped Santa Maria Terni, Terni, Italy

[8] The Christie, Manchester, Lancs, England

[9] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[10] Levine Canc Inst Atrium Hlth, Charlotte, NC USA

[11] Clin Res Alliance, New Hyde Pk, NY USA

[12] Univ Coll London NHS Fdn Trust, Dept Haematol, London, England

[13] UCLH NIHR Biomed Res Ctr, London, England

[14] Inst Bergonie, Bordeaux, France

[15] Sarah Cannon Res Inst UK, London, England

[16] Univ Virginia Hlth Syst, Charlottesville, VA USA

[17] Paris Univ Diderot, Hop St Louis, APHP, Hematooncol, Paris, France

[18] Ctr Hosp Lyon Sud, Pierre Benite, France

[19] Hop Conception APHM, Marseille, France

[20] Royal Marsden Hosp, London, England

[21] Fak Nemocnice Kralovske Vinohrady, Prague, Czech Republic

[22] BeiGene BeifingCo Ltd, Beijing, Peoples R China

[23] BeiGene USA Inc, Cambridge, MA USA

[24] Monash Hlth, Clayton, Vic, Australia

[25] Monash Univ, Clin Haematol Unit, Clayton, Vic, Australia

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

C044

引用

页码：35 / 35

页数：1

共 50 条

[21] BUDGET IMPACT OF ZANUBRUTINIB TO TREAT RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA FROM A PAYER PERSPECTIVE IN THE UNITED STATES
Liu, S.
Yang, K.
Carter, J.
Zimmerman, T.
Tang, B.
VALUE IN HEALTH, 2022, 25 (01) : S62 - S62
[22] A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial
Oh, Sung Yong
Kim, Won Seog
Kim, Jin Seok
Chae, Yee Soo
Lee, Gyeong-Won
Eom, Hyeon Seok
Ryoo, Hun Mo
Lee, Suee
Kim, Seok Jin
Yoon, Dok Hyun
Won, Jong Ho
Hong, Junshik
Park, Jinny
Lee, Sang-Min
Hong, Jung Yong
Park, Eunkyung
Kim, Hyo Jung
Yang, Deok-Hwan
Kim, Hyo-Jin
Suh, Cheolwon
LEUKEMIA & LYMPHOMA, 2016, 57 (06) : 1406 - 1412
[23] Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study
Deng, Lijuan
Li, Zhiming
Zhang, Huilai
Huang, Haiwen
Hu, Jianda
Liu, Lihong
Liu, Ting
Jin, Jie
Zhu, Zunmin
Li, Wenyu
Huang, Zhenqian
Huang, Wenrong
Zhou, Keshu
Yang, Haiyan
Zhang, Mingzhi
Ding, Kaiyang
Zhou, Hui
Hu, Yu
Shuang, Yuerong
Cao, Junning
Gao, Sujun
Li, Dengju
Sun, Zimin
Zhang, Qingyuan
Yi, Shuhua
Ji, Chunyan
Zhang, Liansheng
Hou, Cheng
Du, Yue
Wang, Weige
Zhao, Renbin
Song, Yuqin
Zhu, Jun
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1742 - 1750
[24] Advances in the treatment of relapsed/refractory marginal zone lymphoma
Wang, Haotian
Wan, Xin
Zhang, Ying
Guo, Jing
Bai, Ou
FRONTIERS IN ONCOLOGY, 2024, 14
[25] Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
Zhang, Huilai
Zhou, Keshu
Cheng, Ying
Zhang, Liling
Yang, Haiyan
Zou, Liqun
Cao, Junning
Huang, Huiqiang
Guo, Ye
Wang, Zhao
Huang, Sha
Liang, Zhiyu
Yao, Hui
Guo, Haiyi
Fang, Yiqian
Zhu, Hongjie
BLOOD, 2022, 140 : 3750 - 3751
[26] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Lynch, Ryan C.
Paneesha, Shankara
Avigdor, Abraham
McKinney, Matthew S.
Wahlin, Bjorn E.
Hrom, John S.
Belada, David
Canales, Miguel
Cunningham, David
Devizzi, Liliana
Morley, Nicholas
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Trneny, Marek
BLOOD, 2020, 136
[27] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Lynch, Ryan C.
Paneesha, Shankara
Avigdor, Abraham
McKinney, Matthew S.
Wahlin, Bjorn E.
Hrom, John S.
Belada, David
Canales, Miguel
Cunningham, David
Devizzi, Liliana
Morley, Nicholas
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Trneny, Marek
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 12
[28] Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma
Kim, T. M.
Taszner, M.
Novelli, S.
Cho, S. -G
Villasboas, J. C.
Merli, M.
Jimenez-Ubieto, A.
Tessoulin, B.
Poon, L. M.
Tucker, D.
Walewski, J.
Yi, S.
Song, Y.
Chong, G.
Bachy, E.
Guidez, S.
Alonso, A.
Jagadeesh, D.
Zhang, W.
Magnano, L.
Iskierka-Jazdzewska, E.
Tani, M.
Shen, B.
Uppala, A.
Zhu, M.
Shariff, S.
Brouwer-Visser, J.
Chaudhry, A.
Mohamed, H.
Ambati, S.
Luminari, S.
ANNALS OF ONCOLOGY, 2024, 35 (11) : 1039 - 1047
[29] Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Chen, Robert
Zinzani, Pier Luigi
Fanale, Michelle A.
Armand, Philippe
Johnson, Nathalie A.
Brice, Pauline
Radford, John
Ribrag, Vincent
Molin, Daniel
Vassilakopoulos, Theodoros P.
Tomita, Akihiro
von Tresckow, Bastian
Shipp, Margaret A.
Zhang, Yinghua
Ricart, Alejandro D.
Balakumaran, Arun
Moskowitz, Craig H.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2125 - +
[30] Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma
Cavalloni, Chiara
Varettoni, Marzia
Rattotti, Sara
Arcaini, Luca
EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (13) : 1643 - 1649

← 1 2 3 4 5 →